Back
National Research 10K Form
Sell
34
NRC
National Research
Last Price:
20.37
Seasonality Move:
-0.82%
7 Day Trial
ALL ACCESS PASS
$
7
Key Filings
| 2020-08-07 | 10Q | NRC/National Research Quarterly |
| 2020-05-08 | 10Q | NRC/National Research Quarterly |
| 2020-03-06 | 10K | NRC/National Research Annual |
| 2019-11-08 | 10Q | NRC/National Research Quarterly |
| 2019-08-08 | 10Q | NRC/National Research Quarterly |
| 2019-05-08 | 10Q | NRC/National Research Quarterly |
Receive NRC News And Ratings
See the #1 stock for the next 7 days that we like better than NRC
NRC Financial Statistics
Sales & Book Value
| Annual Sales: | $148.58M |
|---|---|
| Cash Flow: | $1.52M |
| Price / Cash Flow: | 0 |
| Annual Sales: | $1.47 |
| Price / Book: | 14.4 |
Profitability
| EPS (TTM): | 1.13000 |
|---|---|
| Net Income (TTM): | $27.08M |
| Gross Margin: | $92.57M |
| Return on Equity: | 61.94% |
| Return on Assets: | 22.04% |
National Research Earnings Forecast
Key National Research Financial Ratios
- The Gross Profit Margin over the past 31 years for NRC is 62.30%.
- The Selling, General & Administrative Expenses for NRC have been equal to 31.38% of Gross Profit Margin.
- The Interest Expense is 2.78% of Operating Income.
- The Net Earning history of NRC is 20.84% of Total Revenues.
- Per Share Earnings over the last 31 years have been positive in 20 years.
National Research Stock Price Chart
Industry, Sector and Symbol
| Stock Exchange: | NASDAQ |
|---|---|
| Industry: | Health Care Providers & Services |
| Sector: | Health Care |
| Current Symbol: | NRC |
| Website: | nrchealth.com |
Debt
| Debt-to-Equity Ratio: | 1.55 |
|---|---|
| Current Ratio: | 0.47 |
| Quick Ratio: | 0.33 |
Price-to-Earnings
| Trailing P/E Ratio: | 16.99 |
|---|---|
| Forward P/E Ratio: | 0 |
NRC Technical Analysis vs Fundamental Analysis
Sell
34
National Research (NRC)
is a Sell
Is National Research a Buy or a Sell?
-
National Research stock is rated a Sell
The current National Research [NRC] share price is $21.24. The Score for NRC is 34, which is 32% below its historic median score of 50, and infers higher risk than normal.